<DOC>
	<DOCNO>NCT02377999</DOCNO>
	<brief_summary>An exploratory open label , single treatment trial anogenital wart Picato® repeat 2 time two week interval .</brief_summary>
	<brief_title>Safety Efficacy Repeat Use Picato® 0.05 % Treatment Anogenital Warts</brief_title>
	<detailed_description>The purpose present trial explore safety , tolerability efficacy treat GW Picato® 0.05 % gel . The primary outcome measure relate safety tolerability consist severity local reaction treat area ; treatment-related adverse event ( AEs ) serious AEs .</detailed_description>
	<mesh_term>Warts</mesh_term>
	<mesh_term>Condylomata Acuminata</mesh_term>
	<criteria>1 . A clinical diagnosis external anogenital/perianal wart least 2 wart 20 wart locate one follow anatomic location : 1 . In sex : inguinal , perineal , perianal area 2 . In men : penis shaft , scrotum , glans penis foreskin 3 . In woman : vulva 2 . Subjects total wart area least 10 mm2 , 500 mm2 3 . Female subject childbearing potential must confirm pregnant negative urine pregnancy test prior trial treatment 1 . Subject receive topical and/or destructive treatment external anogenital wart within 4 week ( within 12 month imiquimod within 12 week sinecatechins ) prior enrolment 2 . Subject suffer follow condition : 1 . Known human immunodeficiency virus ( HIV ) infection 2 . An outbreak herpes genitalis wart area within 4 week prior enrolment 3 . Has internal ( rectal urethral , vaginal/cervical ) wart require undergoing treatment 4 . Has dermatological disease ( e.g . psoriasis ) skin condition wart area 3 . Subjects use systemic virostatic compound immunosuppressive medication within 30 day prior enrollment 4 . Prior quadrivalent HPV vaccination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>